<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501267</url>
  </required_header>
  <id_info>
    <org_study_id>B3C109868</org_study_id>
    <nct_id>NCT00501267</nct_id>
  </id_info>
  <brief_title>A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder</brief_title>
  <official_title>A Randomized, Repeat Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Solabegron (GW427353) in Combination With Oxybutynin in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of repeat doses of solabegron and
      oxybutynin when taken alone or together
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absorption rate of solabegron and oxybutynin</measure>
    <time_frame>as measured by multiple blood draws after repeat dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess bladder function</measure>
    <time_frame>prior to dosing Session 1 and post dose for each session</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solabegron and oxybutynin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males &amp; females ages 18-65;

          -  Body weight &gt;50kg; BMI between 19-32;

          -  Signed and dated informed consent; QTc Interval &lt;450 msec;

        Exclusion Criteria:

          -  Resting blood pressure &gt;140/90 mmHg or HR &gt;100 at screening;

          -  History of drug allergy or other allergy which, in the opinion of the PI,
             contraindicates their participation;

          -  Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing;

          -  Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or
             vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and
             during study;

          -  history of urinary retention, gastric retention, and other sever gastrointestinal
             motility conditions, uncontrolled narrow-angle glaucoma or who are at risk for these
             conditions;

          -  history of chronic constipation and/or regular laxative use; donation of more than
             500mL of blood within 56 days prior to dosing;

          -  clinically relevant abnormality identified during screening process or any medical
             condition or circumstance making the subject unsuitable for participation based on the
             Investigators assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>solabegron,</keyword>
  <keyword>oxybutynin,</keyword>
  <keyword>healthy adults,</keyword>
  <keyword>drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Solabegron</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

